Table 2.
Differential expression of human chemokine genes in PBMC of RA patients
| Box | Genes | % Reduction |
|---|---|---|
| 1 | MCP-1 | UD |
| 2 | TARC | 53·7 (28·4–55·9) |
| 3 | MDC | 38·7 (13·0–54·3) |
| 4 | MPIF-1 | 54·3 (38·6–61·5) |
| 5 | I-309 | 36·4 (7·5–62·2) |
| 6 | IL-15 | 30·5 (5·0–49·2) |
| 7 | CCR2 | 32·0 (−5·7–47·3) |
| 8 | CCR4 | 30·4 (26·6–53·0) |
| 9 | TECK (thymus-expressed chemokine) | 44·4 (14·7–46·1) |
| 10 | MIP-1 beta | 10·8 (3·5–23·5) |
The percentage reduction of gene expression level before and after combination treatment with leflunomide and MTX was assessed by the difference in luminescence intensity using human inflammatory cytokine/receptor GEArray™ Q Series Kit (SuperArray), and calculated as [(intensity after leflunomide – intensity before leflunomide)/intensity before leflunomide × 100%] with GAPDH as an internal control. UD = undetectable for the gene expression of MCP-1 in both week 0 (before leflunomide addition) and week 24 (after leflunomide addition). Positions of genes were indicated by number-labelled boxes shown in Fig. 2. Results are expressed as median (interquartile range) of the percentage reduction in the cohort of nine RA patients.